🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT05789758Muscular Atrophy, Spinal
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
London, Portsmouth, Canterbury, Central Middlesbrough
2023-12-15
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Active, closed
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105GIST
Deciphera Pharmaceuticals, LLC
Phase 3
54
London, Leeds
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Generate Biomedicines
Phase 1
156
London, Manchester, Merthyr Tydfil
2023-12-12
Active, closed
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237Rett Syndrome
Taysha Gene Therapies, Inc.
Phase 1/2
6
London
2023-12-12
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
London
2023-12-08
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Aura Biosciences
Phase 3
108
London, Sheffield
2023-12-06
Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT06246136Open Angle Glaucoma
Elios Vision, Inc.
Not applicable
194
East Grinstead, Edinburgh, Guildford, London, Manchester
2023-12-05
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Cambridge, Leeds, London, Manchester
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
AnaptysBio, Inc.
Phase 2
132
Belfast, Cambridge, Liverpool, London, Runcorn, Shrewsbury, York
2023-12-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
Akero Therapeutics, Inc
Phase 3
1,650
Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne
2023-12-01
Active, closed
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
NCT06150183Advanced Malignant Solid Tumor
BioNTech SE
Phase 1
41
London, Manchester, Newcastle
2023-11-30
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
NCT06166056Bronchiectasis
Chiesi Farmaceutici S.p.A.
Phase 1/2
45
Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton
2023-11-29
Active, closed
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
NCT06128564Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
13
London, Oxford
2023-11-29
Recruiting
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
NCT06212947Hypochondroplasia
BioMarin Pharmaceutical
Observational
400
London, Glasgow
2023-11-27
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 1
127
Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire
2023-11-27
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Active, closed
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531Hyperphagia in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc.
Phase 3
170
Birmingham, Glasgow, London
2023-11-27
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
Novartis Pharmaceuticals
Phase 2/3
232
London
2023-11-24
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
London, Edinburgh
2023-11-20
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Recruiting
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
NCT06173518Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Autolus Limited
Phase 1
30
London, Manchester, Newcastle upon Tyne
2023-11-16
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Sutton, London
2023-11-14
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NCT06193902Tumor, Solid
Leucid Bio
Phase 1/2
17
London, Manchester
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Recruiting
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729Pulmonary Sarcoidosis
Xentria, Inc.
Phase 1/2
94
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
Akero Therapeutics, Inc
Phase 3
700
Liverpool, London, Newcastle upon Tyne
2023-11-10
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Pfizer
Phase 3
1,571
Isleworth, Southampton, London
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Cardiff, Dundee, Glasgow, London, York
2023-11-07
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
London
2023-11-06
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
By invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
NCT06066580Becker Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
260
Salford, London, Newcastle
2023-11-02
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Leeds, London, Manchester
2023-10-26
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
Nuvectis Pharma, Inc.
Phase 1
140
Edinburgh, London
2023-10-26
Recruiting
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758Solid Tumours
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Birmingham, Blackpool, Bury St Edmunds, Colchester, London, Truro
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
BeOne Medicines
Phase 2
114
Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth
2023-10-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.
Phase 2
260
Liverpool, Belfast, Birmingham, Cambridge, London
2023-10-18
Recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease
W.L.Gore & Associates
Not applicable
244
Canterbury, London, Southampton
2023-10-17
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
Celgene
Phase 3
79
Birmingham, London
2023-10-16
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
684
Harrow, London, Reading, Salford
2023-10-12
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
Active, closed
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649Vitiligo
Clinuvel, Inc.
Phase 3
200
London, Manchester
2023-10-11
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 3
306
London, Birmingham, Chapel Allerton
2023-10-03
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
AbbVie
Phase 3
90
London
2023-10-02
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
London, Middlesbrough, Stoke-on-Trent, Wolverhampton
2023-09-29
By invitation
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT05967351Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
400
London, Oxford, Newcastle upon Tyne
2023-09-27
Active, closed
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Active, closed
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
London
2023-09-22
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
Active, closed
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06052306Metastatic Castration-resistant Prostate Cancer
Bayer
Phase 1
232
Cambridge, London, Sutton, Newcastle upon Tyne
2023-09-20
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
Denali Therapeutics Inc.
Phase 2/3
99
Birmingham, London, Manchester
2023-09-20
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Phase 1/2
22
London
2023-09-15
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
687
Edinburgh, London
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
GlaxoSmithKline
Phase 2/3
300
Wakefield, Birmingham, Leeds, London, Portsmouth
2023-09-13
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
argenx
Phase 3
240
Liverpool, London, Salford
2023-09-12
Recruiting
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938Community-acquired Pneumonia
Biotest
Phase 3
590
Plymouth, London, Glasgow, Guildford, Cardiff
2023-09-09
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG
Phase 2
80
Birmingham, Cambridge, Liverpool, London, Manchester, Preston
2023-09-07
Recruiting
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
NCT06092034Danon Disease
Rocket Pharmaceuticals Inc.
Phase 2
14
London
2023-09-05
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Leicester, London
2023-09-01
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics
Phase 3
500
Dundee, Glasgow, Liverpool, London, Oxford
2023-08-31
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
AnaptysBio, Inc.
Phase 2
420
London, Manchester
2023-08-31
By invitation
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
NCT05883748Erythropoietic Protoporphyria
Disc Medicine, Inc
Phase 2/3
230
London, Dundee, Salford
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.
Phase 3
350
Birmingham, Glasgow, London
2023-08-31
Rows per page Showing 1001–1100 of 2005
Previous 9 10 11 12 13 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=11

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.